Sign in
EVAX Stock Price, Chart, Stats & News
Evaxion Biotech A/S
Save
Evaxion Biotech A/S (EVAX) does not currently pay a dividend.
20.21M
Market cap
–
Current P/E
3.57x
Forward P/E
EVAX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | -122.66% |
Pretax margin | -114.44% |
Net margin | -102.38% |
Effective tax rate | 10.54% |
ROA | -27.21% |
ROE | -61.62% |
D/E | 0.44x |
Interest coverage ratio | -10.54x |
EVAX valuation
P/E | – |
P/S | 2.94x |
P/B | 1.32x |
P/CF | -3.39x |
P/FCF | -3.34x |
P/OCF | -3.39x |
PEG | -0.06x |
EV multiple | -4.39x |
About
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers.
Similar securities
Based on sector and market capitalization
Report issue